1. Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

3. 2013 ACC/AHA Cholesterol Guidelines Statin Initiation Recommendations

4. Multiple Challenges in Statin Selection

5. Intensity of Statin Therapy

6. 2013 ACC/AHA Cholesterol Guidelines Statin Safety Recommendations

7. Unified Definition of Statin Intolerance

8. Selected Drug Interactions That Increase Statin Levels

9. Before Initiating Statin Therapy

10. Statins and Risk for New-Onset T2D

11. T2D Risk Increases With Statin Potency Meta-Analysis of 5 Clinical Trials

12. Risk of T2D Lower With Some Statins

13. Polypharmacy and Drug-Drug Interactions

14. Interprofessional Team Approach Improving Statin Therapy

15. REAL-CAD

16. REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/UA

17. REAL-CAD: Secondary Composite Endpoint

18. REAL-CAD Safety Outcomes

19. Case: Statin-Naive Patient With CAD Patient Background

20. Case (cont) Laboratory Findings

21. Case (cont) Initial Treatment

22. Case (cont) Patient Discontinued Atorvastatin Due to AE

23. Case (cont) Switching to Rosuvastatin

24. Case (cont) Switching to Pitavastatin

25. Clinical Pearls From Case

26. Management of Statin-Related AEs

27. Spectrum of Statin-Associated Muscle AEs

28. Risk Factors for Statin-Associated Muscle AEs

29. Reasons for Increased ASCVD Risk in HIV Infection

30. Use of Statins With PIs

31. 2013 ACC/AHA Cholesterol Guidelines Initiating Statin Therapy in Individuals With Clinical ASCVD

32. Greater LDL-C Reduction With High- vs Low-Intensity Statin

33. IMPROVE-IT: Benefit With Ezetimibe

34. Take Home Messages

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)